MA50440A - Imidazopyridinamides substituées et leur utilisation - Google Patents

Imidazopyridinamides substituées et leur utilisation

Info

Publication number
MA50440A
MA50440A MA050440A MA50440A MA50440A MA 50440 A MA50440 A MA 50440A MA 050440 A MA050440 A MA 050440A MA 50440 A MA50440 A MA 50440A MA 50440 A MA50440 A MA 50440A
Authority
MA
Morocco
Prior art keywords
imidazopyridinamides
substituted
imidazopyridinamides substituted
Prior art date
Application number
MA050440A
Other languages
English (en)
Inventor
Karl Collins
Till Freudenberger
Kersten Matthias Gericke
Walter Kroh
Kirsten Leineweber
Mario Lobell
Daniel Meibom
Jutta Meyer
Thomas Mondritzki
Klaus Münter
Hernandez Nuria Ortega
Jens Schamberger
Nina Alexandra Scheerer
Jan Stampfuss
Alexander Straub
Frank Wunder
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60162133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50440(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of MA50440A publication Critical patent/MA50440A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
MA050440A 2017-10-24 2018-10-18 Imidazopyridinamides substituées et leur utilisation MA50440A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17198021 2017-10-24

Publications (1)

Publication Number Publication Date
MA50440A true MA50440A (fr) 2020-09-02

Family

ID=60162133

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050440A MA50440A (fr) 2017-10-24 2018-10-18 Imidazopyridinamides substituées et leur utilisation

Country Status (27)

Country Link
US (1) US20200339567A1 (fr)
EP (1) EP3700903A1 (fr)
JP (1) JP2021500366A (fr)
KR (1) KR20200076686A (fr)
CN (1) CN111225917A (fr)
AR (1) AR113790A1 (fr)
AU (1) AU2018354785A1 (fr)
BR (1) BR112020007967A2 (fr)
CA (1) CA3084422A1 (fr)
CL (1) CL2020001075A1 (fr)
CO (1) CO2020004968A2 (fr)
CR (1) CR20200173A (fr)
CU (1) CU20200041A7 (fr)
DO (1) DOP2020000072A (fr)
EA (1) EA202091020A1 (fr)
EC (1) ECSP20023043A (fr)
IL (1) IL273954A (fr)
JO (1) JOP20200073A1 (fr)
MA (1) MA50440A (fr)
MX (1) MX2020004190A (fr)
NI (1) NI202000029A (fr)
PE (1) PE20201280A1 (fr)
PH (1) PH12020550472A1 (fr)
SG (1) SG11202003641RA (fr)
TW (1) TW201932462A (fr)
UY (1) UY37947A (fr)
WO (1) WO2019081353A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
AU2019297361A1 (en) 2018-07-05 2021-02-25 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020216669A1 (fr) * 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Imidazopyridinamides substitués par un phényle et leur utilisation
WO2023086390A1 (fr) * 2021-11-09 2023-05-19 Tufts Medical Center, Inc. Procédés et compositions pour fournir une protection myocardique et traiter le stress myocardique et la fibrose
CN117510444B (zh) * 2024-01-06 2024-03-08 成都瑞尔医药科技有限公司 一种呋塞米的精制工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
CA2407573C (fr) 2000-04-27 2011-09-13 Yamanouchi Pharmaceutical Co. Ltd. Derives d'imidazopyridine
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2003008387A1 (fr) 2001-07-20 2003-01-30 Oy Juvantia Pharma Ltd Composes utiles pour le traitement ou la prevention d'une maladie induite par l'alpha-2b-adrenorecepteur
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2008027812A2 (fr) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Dérivés d'imidazopyridine et d'imidazopyrimidine
WO2008134553A1 (fr) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Procédés de traitement de maladies associées aux canaux sodiques au moyen de composés bicycliques
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
WO2010033393A1 (fr) 2008-09-17 2010-03-25 Allergan, Inc. 3-amino-1-oxo ou thioxo-1,2,5,6,7,8-hexahydro-2,7-naphtyridine-4-carbonitriles substitués en tant qu'antagonistes sélectifs d'alpha-2b
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
AU2011219746B2 (en) 2010-02-27 2015-04-23 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
DE102010021637A1 (de) * 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
WO2012105594A1 (fr) * 2011-02-01 2012-08-09 協和発酵キリン株式会社 Dérivé hétérocylique à cycles fusionnés
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
CA2877550C (fr) 2012-07-13 2020-09-08 Ucb Biopharma Sprl Derives d'imidazopyridine utilisables en tant que modulateurs de l'activite tnf
NZ702977A (en) 2012-07-20 2017-10-27 Bayer Pharma AG 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
EP2961755B1 (fr) * 2013-03-01 2017-10-18 Bayer Pharma Aktiengesellschaft Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante
MX2017005479A (es) 2014-11-03 2017-07-04 Bayer Pharma AG Derivados de feniltriazol sustituido con hidroxialquilo y sus usos.

Also Published As

Publication number Publication date
MX2020004190A (es) 2020-08-03
CA3084422A1 (fr) 2019-05-02
TW201932462A (zh) 2019-08-16
AR113790A1 (es) 2020-06-10
CO2020004968A2 (es) 2020-05-05
CL2020001075A1 (es) 2021-01-22
EA202091020A1 (ru) 2020-07-24
JOP20200073A1 (ar) 2020-04-29
KR20200076686A (ko) 2020-06-29
CN111225917A (zh) 2020-06-02
WO2019081353A1 (fr) 2019-05-02
AU2018354785A1 (en) 2020-04-23
NI202000029A (es) 2020-10-09
CU20200041A7 (es) 2021-03-11
ECSP20023043A (es) 2020-06-30
DOP2020000072A (es) 2020-08-31
PH12020550472A1 (en) 2021-03-15
CR20200173A (es) 2020-06-26
JP2021500366A (ja) 2021-01-07
IL273954A (en) 2020-05-31
UY37947A (es) 2019-05-31
US20200339567A1 (en) 2020-10-29
BR112020007967A2 (pt) 2020-10-20
PE20201280A1 (es) 2020-11-24
SG11202003641RA (en) 2020-05-28
EP3700903A1 (fr) 2020-09-02

Similar Documents

Publication Publication Date Title
MA44225A (fr) Sulfonylurées et composés apparentés et leur utilisation
MA43260A (fr) Liants pd1 et/ou lag3
MA47440A (fr) Sulfonylurées, composés apparentés, et leur utilisation
MA45709A (fr) Composés diazahétérobicycliques substitués et leur utilisation
DK3227342T3 (da) Proteinøs heterodimer og anvendelse deraf
MA50440A (fr) Imidazopyridinamides substituées et leur utilisation
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
MA45613A (fr) Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique
DK3379690T3 (da) Hurtigopladningsfremgangsmåde og -system
MA45113A (fr) Composés mic-1 et leur utilisation
MA47311A (fr) Anticorps anti-tgf-bêta et leur utilisation
MA44056A (fr) Anticorps anti-rispéridone et leur utilisation
MA51224A (fr) Composés de sulfonamide et leur utilisation
MA44777A (fr) Anticorps humanisés anti-basigine et leur utilisation
MA49905A (fr) Polyesteramines et polyesterquats
UA38793S (uk) Акумуляторна батарея
DK3672948T3 (da) Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3645090T3 (da) Inhalator
MA46235A (fr) 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation
MA40524A (fr) Dérivés d'adrénomédulline stabilisés et leur utilisation
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
MA41587A (fr) N-(4-hydroxy-4-méthylcyclohexyl)-4-phénylbenzènesulfonamides et n-(4-hydroxy-4-méthylcyclohexyl)-4-(2-pyridyl)benzènesulfonamides et leur utilisation thérapeutique
DK3714215T3 (da) Affugtningssystem og -fremgangsmåde
IT201700039351A1 (it) Miscela antimeristematica e antigermogliante